Search tool

The 2014 Work programme continues to implement the commitments set out in the EMCDDA’s 2013–15 strategy and work programme. It builds on the achievements made in 2013 where measures were put in...

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the...

The EMCDDA–Europol Joint Report on new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine, commonly known by the abbreviation ‘25I-NBOMe’, submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After...

The EMCDDA–Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the...

The EMCDDA–Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the...

The EMCDDA–Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the...

Concerns about the availability and use of methamphetamine in Europe have been growing for some time. Historically, the use of methamphetamine has been confined largely to the Czech Republic and Slovakia; however...

This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and...

This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole (5-IT), that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability...

This study explores the civil society organisations that engage in drug policy advocacy in Europe. An Internet search in English, French and Spanish combined with information from national sources in 30 countries...